Strategies to Reduce Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

被引：10

作者：

Mawad, Raya ^{[1
,2
]}

Lionberger, Jack M. ^{[3
]}

Pagel, John M. ^{[1
,2
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA

[2] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA

[3] St Louis Univ, Dept Med, Div Hematol Oncol, St Louis, MO 63103 USA

来源：

CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 2013年 / 8卷 / 02期

关键词：

Acute myeloid leukemia; Allogeneic hematopoietic cell transplant; Relapse; Strategies; VERSUS-HOST-DISEASE; ACUTE MYELOGENOUS LEUKEMIA; BONE-MARROW-TRANSPLANTATION; DONOR LEUKOCYTE INFUSIONS; WT1 PEPTIDE VACCINATION; PROGNOSTIC-SIGNIFICANCE; OLDER PATIENTS; CYTOGENETIC ABNORMALITIES; HEMATOLOGIC MALIGNANCIES; COMPLETE REMISSION;

D O I：

10.1007/s11899-013-0153-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The incidence of acute myeloid leukemia (AML) is expected to increase in conjunction with our ageing population. Although it is proving to be a heterogeneous disease process, the only treatment with proven survival benefit for poor risk AML remains allogeneic hematopoietic cell transplant. Although this is presumed to be a curative strategy, many patients relapse after transplant, prompting us to examine various ways that we can improve outcomes. These efforts involve every step of AML diagnostics and therapy, including the intricate processes of conditioning, graft manipulation and immunomodulation. The hope is that improvement in these steps will ultimately improve survival and decrease relapse rates for AML patients after transplant.

引用

页码：132 / 140

页数：9

共 58 条

[1] Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry [J].

Al-Mawali, Adhra ;

Gillis, David ;

Hissaria, Pravin ;

Lewis, Ian .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 129 (06) :934-945

[2] Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life [J].

Alatrash, Gheath ;

de Lima, Marcos ;

Hamerschlak, Nelson ;

Pelosini, Matteo ;

Wang, Xuemei ;

Xiao, Lianchun ;

Kerbauy, Fabio ;

Chiattone, Alexandre ;

Rondon, Gabriela ;

Qazilbash, Muzaffar H. ;

Giralt, Sergio A. ;

Silva, Leandro de Padua ;

Hosing, Chitra ;

Kebriaei, Partow ;

Zhang, Weiqing ;

Nieto, Yago ;

Saliba, Rima M. ;

Champlin, Richard E. ;

Andersson, Borje S. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (10) :1490-1496

[3] NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies [J].

Alyea, Edwin P. ;

DeAngelo, Daniel J. ;

Moldrem, Jeffrey ;

Pagel, John M. ;

Przepiorka, Donna ;

Sadelin, Michel ;

Young, James W. ;

Giralt, Sergio ;

Bishop, Michael ;

Riddell, Stan .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (08) :1037-1069

[4] Clofarabine ± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS [J].

Andersson, Borje S. ;

Valdez, Benigno C. ;

de Lima, Marcos ;

Wang, Xuemei ;

Thall, Peter F. ;

Worth, Laura L. ;

Popat, Uday ;

Madden, Timothy ;

Hosing, Chitra ;

Alousi, Amin ;

Rondon, Gabriela ;

Kebriaei, Partow ;

Shpall, Elizabeth J. ;

Jones, Roy B. ;

Champlin, Richard E. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (06) :893-900

[5] Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation:: a phase 1/2 study [J].

André-Schmutz, I ;

Le Deist, F ;

Hacein-Bey-Abina, S ;

Vitetta, E ;

Schindler, J ;

Chedeville, G ;

Vilmer, E ;

Fischer, A ;

Cavazzana-Calvo, M .

LANCET, 2002, 360 (9327) :130-137

[6] Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning [J].

Baron, F ;

Maris, MB ;

Sandmaier, BM ;

Storer, BE ;

Sorror, M ;

Diaconescu, R ;

Woolfrey, AE ;

Chauncey, TR ;

Flowers, MED ;

Mielcarck, M ;

Maloney, DG ;

Storb, R .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1993-2003

[7] 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation [J].

Bolanos-Meade, Javier ;

Smith, B. Douglas ;

Gore, Steven D. ;

McDevitt, Michael A. ;

Luznik, Leo ;

Fuchs, Ephraim J. ;

Jones, Richard J. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (05) :754-758

[8]

Burton E, 2011, NOVEL INHIBITOR PLX3

[9] Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461) [J].

Byrd, JC ;

Mrózek, K ;

Dodge, RK ;

Carroll, AJ ;

Edwards, CG ;

Arthur, DC ;

Pettenati, MJ ;

Patil, SR ;

Rao, KW ;

Watson, MS ;

Koduru, PRK ;

Moore, JO ;

Stone, RM ;

Mayer, RJ ;

Feldman, EJ ;

Davey, FR ;

Schiffer, CA ;

Larson, RA ;

Bloomfield, CD .

BLOOD, 2002, 100 (13) :4325-4336

[10] Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell Transplantation [J].

Chen, Yiming ;

Cortes, Jorge ;

Estrov, Zeev ;

Faderl, Stefan ;

Qiao, Wei ;

Abruzzo, Lynne ;

Garcia-Manero, Guillermo ;

Pierce, Sherry ;

Huang, Xuelin ;

Kebriaei, Partow ;

Kadia, Tapan ;

De Lima, Marcos ;

Kantarjian, Hagop ;

Ravandi, Farhad .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) :2507-2513

← 1 2 3 4 5 6 →